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Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone supplementation may
reduce the risk of miscarriage in women with recurrent or threatened miscarriage. Cochrane Reviews summarized the evidence and found
that the trials were small with substantial methodologic weaknesses. Since then, the effects of first-trimester use of vaginal micronized
progesterone have been evaluated in 2 large, high-quality, multicenter placebo-controlled trials, one targeting women with unexplained
recurrent miscarriages (the PROMISE [PROgesterone in recurrent MIScarriagE] trial) and the other targeting women with early pregnancy
bleeding (the PRISM [PRogesterone In SpontaneousMiscarriage] trial). The PROMISE trial studied 836women from45 hospitals in the United
Kingdom and the Netherlands and found a 3% greater live birth rate with progesterone but with substantial statistical uncertainty. The PRISM
trial studied 4153women from48 hospitals in the United Kingdomand found a 3%greater live birth rate with progesterone, but with a P value
of .08. A key finding, first observed in the PROMISE trial, and then replicated in the PRISM trial, was that treatment with vaginal micronized
progesterone 400 mg twice daily was associated with increasing live birth rates according to the number of previous miscarriages. Pre-
specified PRISM trial subgroup analysis in womenwith the dual risk factors of previousmiscarriage(s) and current pregnancy bleeding fulfilled
all 11 conditions for credible subgroup analysis. For the subgroup of women with a history of 1 or more miscarriage(s) and current pregnancy
bleeding, the live birth rate was 75% (689/914) with progesterone vs 70% (619/886) with placebo (rate difference 5%; risk ratio, 1.09, 95%
confidence interval, 1.03e1.15; P¼.003). The benefit was greater for the subgroup of women with 3 or more previous miscarriages and
current pregnancy bleeding; live birth rate was 72% (98/137) with progesterone vs 57% (85/148) with placebo (rate difference 15%; risk
ratio, 1.28, 95% confidence interval, 1.08e1.51; P¼.004). No short-term safety concerns were identified from the PROMISE and PRISM
trials. Therefore, women with a history of miscarriage who present with bleeding in early pregnancy may benefit from the use of vaginal
micronized progesterone 400 mg twice daily. Women and their care providers should use the findings for shared decision-making.
Key words: bleeding, luteal phase deficiency, meta-analysis, recurrent miscarriage, threatened miscarriage, vaginal micronized progesterone
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Expert Reviews ajog.orgrogesterone is essential for theP establishment and maintenance of
a pregnancy.1 Withdrawal of progester-
one in early pregnancy typically results
in a miscarriage, and antiprogesterone
drugs are powerful inducers of abor-
tion. The central role of progesterone in
early pregnancy led clinicians and re-
searchers to hypothesize that proges-
terone deficiency could be a cause of
some miscarriages. This hypothesis has
resulted in numerous clinical trials of
progesterone supplementation in
women at high risk of miscarriage. The
2 groups of women at particular risk of
miscarriage are those who have a his-
tory of recurrent miscarriage and those
who are bleeding in early pregnancy.
The first randomized trial in women
with recurrent miscarriage was pub-
lished in 1953, and 11 trials followed in
the subsequent decades.2 The first trial
in women with threatened miscarriage
was published in 1987, and since then 7
further trials have been conducted.3
However, these trials used different
progestogens and were small and
methodologically weak, producing
heterogenous and unreliable results.
Policy makers have therefore been un-
able to make evidence-based recom-
mendations on the use of progestogen
supplementation to improve outcomes
in these cohorts of women. For
instance, the American College of Ob-
stetricians and Gynecologists reviewed
the evidence in 2015 and concluded that
“For threatened early pregnancy loss,
the use of progestins is controversial,
and conclusive evidence supporting
their use is lacking. Women who have
experienced at least three prior preg-
nancy losses, however, may benefit from
progesterone therapy in the first
trimester.”4 Similarly, in the United
Kingdom, the National Institute for
Health and Care Excellence concluded
in 2012 that “a very large multicentre
randomised controlled trial of women
receiving treatment with either proges-
terone/progestogen or placebo for
threatened miscarriage should be con-
ducted.”5 The PROMISE (PROgester-
one in recurrent MIScarriagE) and
PRISM (PRogesterone In Spontaneous
Miscarriage) trials were conducted to168 American Journal of Obstetrics& Gynecologygenerate robust evidence on the role of
progesterone therapy to prevent
miscarriage and increase the live birth
rate.
In this review, we critically evaluate
the results from the PROMISE and
PRISM trials to assess what they add to
our existing knowledge. We move
beyond statistical inference to provide a
full scientific inference by taking into
account the context, biological rationale,
biological gradient, external evidence,
and consistency across the studies.6 We
assess the evidence for key prespecified
subgroup effects using robust
guidelines.7e9 Finally, we provide our
recommendations for clinical practice.
Statistical and Scientific Inferences
The New England Journal of Medicine
article on the PRISM trial noted a 3%
increase in live birth rate with vaginal
micronized progesterone, but suggested
it was a negative result, as the P value
associated with this finding was .08.10
However, our interpretation of the
PRISM trial in this review takes into
account the totality of available evidence,
suggesting a potential role for proges-
terone for women at high risk of a
miscarriage. We propose the apparent
discordance between the published New
England Journal of Medicine manu-
script10 and our interpretation relates to
the issue of statistical inference vs sci-
entific inference. Statistical inference
focuses on hypothesis testing. Scientific
inference, in contrast, not only considers
any statistical uncertainty in the findings
but in addition takes into account the full
extent of all other evidence, to make a
considered judgemnt. The American
Statistical Association (ASA) has issued a
series of 44 instructive articles on draw-
ing scientific inferences from studies.11
Appreciation of the key messages from
these ASA articles is essential for making
clinical sense of the PROMISE and
PRISM trials.
The ASA’s statements recommend
that “scientific conclusions or policy
decisions should not be based on only
whether a P-value passes a specific
threshold” and “no single index should
substitute for scientific reasoning.”11
Further, the ASA states that “practicesAUGUST 2020that reduce data analysis or scientific
inference to mechanical ‘bright-line’
rules (such as P<.05, or equivalent con-
fidence intervals) for justifying scientific
claims or conclusions can lead to erro-
neous beliefs and poor decision mak-
ing.”11 The ASA notes “a conclusion
doesn’t immediately become ‘true’ on
one side of the divide (P<.05) and ‘false’
on the other,” and the ASA recommends
that phrases such as “statistically signif-
icant” and “statistically nonsignificant”
are no longer used. Instead, the ASA
recommends that researchers bring
many contextual factors into play to
derive scientific inferences, including the
design of the study, replicability, and
other external evidence.
The PROMISE Trial
The PROMISE Trial12 is a well-powered
randomized trial in women with recur-
rent miscarriage (Table 1). It is a high-
quality trial, with computer-generated
third-party randomization, allocation
concealment, double-blinding, placebo-
control, excellent follow-up rate, and a
prespecified statistical analysis plan
that was diligently implemented.
The primary analysis of the PROMISE
trial found the live birth rate was 66%
(262/398) in the progesterone group vs
63% (271/428) in the placebo group
(risk ratio [RR], 1.04, 95% confidence
interval [CI], 0.94e1.15, P¼.45). There
was a 3% greater live birth rate with
progesterone, but the trial finding was
reported as not statistically significant
due to the large P value (P¼.45) and the
consequent statistical uncertainty. We
then performed a prespecified subgroup
analysis by the number of previous
miscarriages; the study population was
split into 2 subgroups; one included
womenwho had 3 previous miscarriages
and the other included women who had
4 miscarriages. We also performed a
post-hoc subgroup analysis by 3, 4, 5,
and 6 previous miscarriages. We un-
derstood that the post-hoc analysis
would be underpowered and could only
be used for hypothesis generation but
considered that such an analysis would
still be useful for assessing a biological
gradient in these subgroups. The find-
ings (Figure 1) appeared to suggest a
TABLE 1
PROMISE trial: vaginal micronized progesterone in women with unexplained recurrent miscarriages
Population Women with unexplained recurrent miscarriages (3 consecutive
or nonconsecutive miscarriages), trying to conceive naturally
Intervention 400 mg of micronized progesterone taken vaginally twice daily from no later than
6 weeks until 12 weeks of gestation
Comparison Placebo
Primary outcome Live birth beyond 24 weeks
Sample size and power 836 patients randomized; 90% power to detect a 10% difference in live births
Hospitals and countries 36 hospitals in the United Kingdom and 9 hospitals in the Netherlands
PROMISE, PROgesterone in recurrent MIScarriagE.
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number of previous miscarriages.
Although the small sample sizes in the
subgroups and the large P value for test
of subgroup interaction (P¼.41) sug-
gested an inconclusive subgroup effect,
the findings generated a hypothesis that a
subgroup effect existed with a biological
gradient related to the increasing num-
ber of previous miscarriages. As Roth-
well published, “The best test of validity
of subgroup-treatment effect in-
teractions is their reproducibility in
other trials.”7 We were able to assess the
reproducibity of this subgroup effect by
the increasing number of previous mis-
carriages in the PRISM trial.10FIGURE 1
PROMISE trial data on live birth >24 w
Number of previous miscarriages
3
≥ 4
≥ 6
148 / 218
114 / 180
26 / 46
Progesterone (n/N)
Pre-specified Subgroup analysis (P value
All Participants 262 / 398
Number of previous miscarriages
3
4
5
148 / 218
60 / 79
28 / 55
Post-hoc Subgroup analysis
CI, confidence interval; PROMISE, PROgesterone in recurrent MISca
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The PRISM trial is a well-powered ran-
domized trial in women with threatened
miscarriage (Table 2). It was designed
and conducted with methodologic rigor,
with appropriate randomization, allo-
cation concealment, double-blinding
with placebo control, excellent follow-
up rate, and analysis according to a
prespecified statistical analysis plan.
The primary analysis of PRISM trial
found that the live birth rate was 75%
(1513/2025) in the progesterone group
vs 72% (1459/2013) in the placebo group
(RR, 1.03; 95% CI, 1.00e1.07, P¼.08).
For the prespecified subgroup analysis
by the number of previous miscarriages,eeks by the number of previous misca
159 / 236
112 / 192
21 / 41
Placebo (n/N)
 for interaction = 0.52)
271 / 428
0.5 1
Favors Placebo Fa
159 / 236
70 / 103
21 / 48
rriagE.
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subgroups: women without a history of
miscarriage; womenwith 1 or 2 previous
miscarriages; and women with 3 pre-
vious miscarriages, as shown in Figure 2.
There were 2 post-hoc subgroup ana-
lyses: the first grouping women into
those who had no previous miscarriage
or those who had any number of previ-
ous miscarriages; and the second
grouping women by 0, 1, 2, 3 previous
miscarriages, to explore in detail for a
possible biological gradient (Figure 2).
The P values for “subgroup by treat-
ment” interactions were consistent with
differential subgroup effects. The live
birth rate was 75% (689/914) withrriages
1.01 (0.89-1.14)
1.09 (0.92-1.28)
1.10 (0.75-1.63)
Risk Ratio [95% CI]
1.5
vors Progesterone
1.04 (0.94-1.15)
1.01 (0.89-1.14)
1.12 (0.93-1.34)
1.16 (0.77-1.76)
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TABLE 2
PRISM trial: vaginal micronized progesterone in women with threatened miscarriages
Population Women with vaginal bleeding during the first 12 weeks of pregnancy
Intervention 400 mg of micronized progesterone taken vaginally or rectally twice daily from randomization until 16 weeks of gestation
Comparison Placebo
Primary outcome Live birth 34 weeks
Sample size and power 4153 patients randomized, 90% power to pick up a 5% difference in live births
Hospitals 48 hospitals in the United Kingdom
PRISM, PRogesterone In Spontaneous Miscarriage.
Coomarasamy et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol 2020.
Expert Reviews ajog.orgprogesterone vs 70% (619/886) with
placebo (RR, 1.09; 95% CI, 1.03e1.15;
P¼.003) for the subgroup of womenwith
1 or more previous miscarriage(s) and
bleeding in the current pregnancy
(number needed to treat ¼ 20; 95% CI,
19e22). The benefit was even greater for
the subgroup of women with 3 or more
previous miscarriages and current preg-
nancy bleeding; live birth rate was 72%
(98/137) with progesterone vs 57% (85/
148) with placebo (RR, 1.28; 95% CI,
1.08e1.51; P¼.004; number needed to
treat ¼ 8, 95% CI, 7e10).
The findings of the post-hoc sub-
group analyses were in line with the
prespecified subgroup analyses.
Whether we consider the prespecified
or the post-hoc subgroup analyses, inFIGURE 2
PRISM trial data on live birth >34 we
Post Hoc Subgroup
Number of previous miscarriages
0
≥ 1
All Participants
824 / 1111
689 / 914
1513 / 2025
840 / 1
619 / 8
1459 / 2
Number of previous miscarriages
0
1
824 / 1111
413 / 547
840 / 1
367 / 5
2
≥ 3
178 / 230
98 / 137
167 / 23
85 / 14
Number of previous miscarriages
0
1-2
≥ 3
824 / 1111
591 / 777
98 / 137
840 / 1
534 / 7
85 / 1
Progesterone (n/N) Placebo
Pre-Specified Subgroup
CI, confidence interval; PRISM, PRogesterone In Spontaneous Misca
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170 American Journal of Obstetrics& Gynecologyall of these analyses there is a rela-
tionship between the number of pre-
vious miscarriages and the effect
of progesterone, as was already
observed in the PROMISE trial (see
Supplemental Materials and Methods).
The PRISM Trial Subgroup by Number
of Previous Miscarriages: Credibility
When should one believe a subgroup
analysis? Subgroup analyses can suffer
from false-positive results because of
multiple comparisons or false-negative
results from inadequate power. So,
robust guidelines have been developed to
aid in the interpretation of subgroup
analysis.7e9 These guidelines translate
into 11 criteria, 5 on design, 2 on anal-
ysis, and 4 on the context.8 We appliedeks by the number of previous miscarri
127
86
013
0.75 1 1.25
Favors Placebo Favors Progesterone
127
02
6
8
127
38
48
 (n/N)
rriage.
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AUGUST 2020these 11 criteria to the PRISM trial
subgroup analysis by number of previ-
ous miscarriages to assess the credibility
of the subgroup findings.
1. Is the subgroup variable a character-
istic measured at baseline? Subgroups
can be defined by features measured
at baseline before randomization, or
by features emerging after randomi-
zation. As postrandomization fea-
tures can be influenced by the
intervention itself the validity of
findings from subgroups that rely on
postrandomization features can be
compromised. For our subgroups,
the number ofmiscarriages is known
at baseline, before randomization,
thus this criterion is fulfilled.ages
0.99 (0.95-1.04)
1.09 (1.03-1.15)
1.03 (1.00-1.07)
0.01
0.99 (0.95-1.04)
1.04 (0.97-1.12) 0.02
1.08 (0.97-1.19)
1.28 (1.08-1.51)
0.99 (0.95-1.04)
1.05 (1.00-1.12)
1.28 (1.08-1.51)
0.007
Risk Ratio [95% CI] P-value for interaction
- 0.3%
+ 5.5%
1.03 (1.00-1.07)
- 0.3%
+ 2.4%
+ 6.6%
+ 14.1%
- 0.3%
+ 3.7%
+ 14.1%
% difference
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within rather than between studies? A
subgroup effect observed only be-
tween studies, and not within a
study, is unreliable as the subgroup
effect may be due to the heteroge-
neity that is often present between
various studies. A subgroup effect
found within an individual study is
more credible. The subgroup effect
we identified was within the PRISM
study itself, so this criterion is met.
3. Was the hypothesis specified a priori?
The hypothesis was prespecified in
date-stamped presentations, before
the allocation codes were unblinded
for the PRISM trial (on June 28,
2018).
4. Was the direction of the subgroup ef-
fect specified a priori? The direction
of the effect was indicated in date-
stamped presentations before the
allocation codes were unblinded (on
June 28, 2018).
5. Was the subgroup effect one of a small
number of hypothesised effects tested?
There were 10 prespecified sub-
group analyses in the PRISM pro-
tocol, but only one was considered
to be of special clinical interest; the
remaining subgroup analyses were
useful for consistency checking
across the subgroups. The distinc-
tion between subgroups of “special
interest” and subgroups for “con-
sistency checking” was not
addressed in the PRISM study pro-
tocol but was documented in date-
stamped presentations, predating
the unblinding of PRISM Trial re-
sults on June 28, 2018.
6. Does the interaction test suggest a low
likelihood that chance explains the
apparent subgroup effect? The inter-
action test P value for the subgroups
by the number of previous mis-
carriages was .007, suggesting that it is
unlikely that chance explains the
observed subgroup effect. In contrast,
the subgroup interaction P value was
larger than .1 for all the other pre-
specificed subgroups, suggesting a
subgroup effect was unlikely for all
the other subgroup analyses.
7. Is the significant subgroup effect in-
dependent? Two, or more, subgroupeffects may be related to each other
in such a way that one common
factor explains the subgroup find-
ings. We adjusted for confounding
by key prognostic variables, such as
female age, presense of fetal heart
activity at presentation, estimated
gestation at presentation, and
amount of (patient-reported)
bleeding, and this did not result in
any material change in the interac-
tion test P value.
8. Is the size of the subgroup effect large?
The relative risk for those with 1 or 2
miscarriages was 1.05 (95% CI,
1.00e1.12) and a 5% difference was
considered important in a survey of
clinicians before the PRISM trial
was conducted. For those with 3 or
more miscarriages, the RR was 1.28
(95% CI, 1.08e1.51). The effect size
is larger for those with a greater
number of previous miscarriages.
9. Is the interaction consistent across the
studies? Increasing benefit with
increasing number of prior mis-
carriages was noted in the PROM-
ISE trial (Figure 1) and the PRISM
trial (Figure 2). The replication of
the subgroup effect (along with the
presence of a biological gradient)
among 2 independent, high-quality
trials gives confidence to the
finding of this subgroup effect.
10. Is the interaction consistent across
closely related outcomes within the
study? We explored this question by
conducting subgroup analyses on
the outcomes of ongoing pregnancy
at 12 weeks, and miscarriage at
gestations less than 24 weeks; these 2
outcomes are closely related to live
birth. A subgroup effect by the
number of previous miscarriages
was observed for the outcomes of
ongoing pregnancy and miscar-
riage. We observed an increase in
ongoing pregnancies and a decrease
in miscarriages according to the
number of previous miscarriages;
these findings are consistent with
the observed live birth subgroup
effect (Figures 3 and 4).
11. Is there indirect evidence that sup-
ports the hypothesized interaction
(biological rationale)? There is veryAUGUST 2020 Amgood biological reasoning to expect
greater effect from progesterone in
those with increasing numbers of
previous miscarriages. Euploid
miscarriage is more likely with
increasing number of previous
miscarriages (Figure 5).13 As one of
the causes of euploid miscarriage is
hypothesized to be luteal phase
defect, progesterone can be ex-
pected to have greater benefit in
those with greater number of pre-
vious miscarriages. Furthermore,
luteal phase defect is likely to pre-
sent with vaginal bleeding, thus
greater benefit from progesterone
use can be expected in women with
early pregnancy bleeding.
Guidelines on the interpretation of
subgroup effects note that “Debates
about subgroup effects may be framed in
terms of absolute acceptance or rejec-
tion”8 but such “yes versus no polarised
approach is undesirable and destructive,
mainly because it ignores the uncertainty
that is inevitably part of such judg-
ments.”8 Furthermore, “An approach
that is more productive and more real-
istic is to place the likelihood that a
subgroup effect is real on a continuum
from ‘highly plausible’ to ‘extremely
unlikely’.. the question is then a deci-
sion of where on this continuum a pu-
tative subgroup effect lies.”8 We propose
the subgroup effect first suggested in the
PROMISE trial, and then confirmed in
the PRISM trial is highly plausible.14
Synthesis of External Evidence
There are several studies of micronized
vaginal progesterone and other pro-
gestogens. Most of these studies are small
and of limited methodologic quality. We
synthesized the evidence from the
PROMISE and PRISM studies first
(Figure 6), following whichwe added the
external evidence from other studies of
progesterone or progestogens (Figure 7)
to check for consistency in the findings
across the various studies. The studies
were broadly consistent in showing a
benefit on live birth or ongoing preg-
nancy rate from the first-trimester use of
progesterone or progestogens, giving
further confidence in our findings.erican Journal of Obstetrics& Gynecology 171
FIGURE 3
Ongoing pregnancy at 12 weeks by the number of previous miscarriages
All Participants 1672 / 2025 1602 / 2013
0.5 1 1.5
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% difference
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The role of first-trimester progester-
one supplementation in the treatment
of pregnancies at high risk of miscar-
riage is a long-standing research
question that has been debated in the
medical literature for more than 60
years. The PROMISE and PRISM trials
are 2 very high-quality trials that have
addressed the effects of first-trimester
use of vaginal micronized progester-
one treatment in women at risk of a
miscarriage.
Biologic plausibility
Approximately one half of all mis-
carriages, including pregnancy losses in
women with recurrent miscarriage, are
due to numeric chromosome errors with
trisomy being the most frequent, espe-
cially with advancing maternal age, fol-
lowed by polyploidy and monosomyFIGURE 4
Miscarriage <24 weeks by the numb
All Participants 410 / 2025 451 / 20
Number of previous miscarriages
0
1-2
≥ 3
229 / 1111
150 / 777
31 / 137
244 / 1
154 / 7
53 / 1
Progesterone (n/N) Placebo
Post Hoc Subgroup
CI, confidence interval.
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172 American Journal of Obstetrics& GynecologyX.15 Such “aneuploid” miscarriages are
thought to occur on a random basis,
meaning that the risk of subsequent
miscarriage is not increased. “Euploid”
miscarriages, in contrast, are more
frequently diagnosed with increasing
number of previous miscarriages, as
shown in Figure 5.
A progesterone-related problem,
often given the name “luteal phase
defect” (LPD), is considered to be one
of the causes of a euploid miscarriage.
The corpus luteum in the ovary pro-
duces progesterone during early preg-
nancy. Progesterone is essential for
maintaining the decidua, and it is hy-
pothesized that a defect in the function
of the corpus luteum can result in low
progesterone levels which in turn may
increase the risk of miscarriage.15
However, there is no clear definition
for LPD, and there are certainly noer of previous miscarriages
13
0.5 1 1.5
Favors Progesterone Favors Placebo
127
38
48
 (n/N)
t miscarriage: a critical evaluation of randomized evidence. Am J
AUGUST 2020reliable tests to identify patients who
may have the condition. Serum and
salivary progesterone have been
used16,17; however, the diagnostic and
prognostic value of the progesterone
level has remained unclear.17,18
Furthermore, direction of causality
confounds interpretation of a proges-
terone result, ie, if the progesterone
level is found to be low in early preg-
nancy, we cannot know whether the
low progesterone is the cause or effect
of a miscarriage. Histologic assessment
of the endometrium, initially proposed
by Noyes et al. in 1950,19 has been
shown to have high interobserver and
intraobserver variation and poorly
discriminates between fertile and
infertile women; therefore, molecular-
based alternatives, in addition to his-
tologic assessment, are being devel-
oped. The endometrium is a dynamic0.91 (0.81-1.01)
0.96 (0.82-1.11)
0.95 (0.78-1.15)
0.58 (0.40-0.83)
0.03
Risk Ratio [95% CI]1 P-value for 
interaction
- 2.6%
- 1%
- 1.6%
- 13.2%
% difference
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FIGURE 5
Miscarriage risk by the number of previous miscarriages
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ajog.org Expert Reviewsmixture of cells, primarily glandular
and stromal, that undergo cycles of
proliferation, differentiation, and
menstruation. Timed evaluation of the
endometrium, particularly in the luteal
phase, is being evaluated critically to
identify “endometrial factors” associ-
ated with recurrent pregnancy loss.
A study by Stephenson et al. reported
on 116 women with a history of recur-
rent early pregnancy loss who were
evaluated in the mid-luteal phase with
an endometrial biopsy for histologic
and immunohistochemical staining for
nuclear CyclinE expression of the
endometrial glands.20,21 Luteal phase
start vaginal micronized progesterone
100 mg every 12 hours was prescribed
based on elevated nuclear CyclinE
expression, with a repeat endometrial
biopsy recommended on the first
treatment cycle, and with increased
dosage of progesterone if CyclinE
expression did not normalize. The live
birth rate was greater in women pre-
scribed luteal phase start vaginal
micronized progesterone compared
with controls, 68% vs 51%; OR, 2.1
(95% CI, 1.0e4.4). From a biological
plausibility perspective, serial endome-
trial biopsies showed the use of vaginal
micronized progesterone resulted in
decreased or normalization of nuclear
CyclinE expression in 84% of women
with initially elevated expression of this
molecular marker.FIGURE 6
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The absence of a meaningful test for
LPD left researchers with the challenge
of not knowing which patients to target
with progesterone treatment. Re-
searchers over the past 6 decades
responded to this challenge by targeting
“enriched” populations, in whom the
overall risk of miscarriage is greater
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AUGUST 2020 Amrecurrent miscarriages and women with
early pregnancy bleeding, the 2 target
populations for the PROMISE and
PRISM trials, respectively.
A history of previous miscarriage
identifies those at risk of a future
miscarriage, and the risk of a future
miscarriage increases with the increasing
number of previous miscarriages
(Figure 8). Specifically, it is the risk of
euploid miscarriages that increases with
increasing number of previous mis-
carriages; meanwhile, the risk of
miscarriage from sporadic aneuploidies
remains broadly constant (Figure 5).
This biological gradient increases ourRisk Ratio
M-H, Fixed, 95% CI
0.9 1 1.1 1.2
vors Placebo Favors Progesterone
f gestation. 
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Expert Reviews ajog.orgconfidence that the history of previous
miscarriage is a valid prognostic marker
for future miscarriage. If one of the
causes of miscarriage is LPD, then the
prevalence of LPD can be expected to
increase with the increasing number of
previous miscarriages. Given this bio-
logical understanding and the hypothe-
sis generated from the PROMISE trial
findings, we considered the number of
previous miscarriages as the most
important subgroup in the PRISM
study.10
Type of progestogen used in the
PROMISE and PRISM trials
We used vaginal, micronized progester-
one in the PROMISE and PRISM trials.174 American Journal of Obstetrics& GynecologyThe results from these trials are
not necessarily generalizable to pro-
gestogens such as dydrogestone or 17-
hydroxyprogesterone. The natural pro-
gesterone used in the PROMISE and
PRISM trials is derived from soybeans
and Mexican yam roots and has an iden-
tical chemical structure to physiological
progesterone synthesised in the human
body.22 Synthetic progestogens, which
include dydrogesterone and 17-hydrox-
yprogesterone, have a different molecular
structure, pharmacodynamics and phar-
macokinetics, as well as a different safety
profile.23 We have restricted our analysis
to progesterone, and our data do not
support or refute the role of other
progesterone-like compounds.AUGUST 2020Implications for clinical practice
In summary, the PRISM and PROMISE
trials found a small but positive treat-
ment effect that seems to be dependent
on the number of miscarriages. Our
analysis did not suggest any benefit from
progesterone therapy for women with
early pregnancy bleeding but no history
of miscarriages. We believe that the dual
risk factors of early pregnancy bleeding
and a history of one or more previous
miscarriage(s) identify high-risk women
in whom progesterone is of benefit. The
question is how this should affect clinical
practice. We recommend that the infor-
mation should be communicated to
women at high risk of miscarriages to
enable shared decision-making. Our
FIGURE 8
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ajog.org Expert Reviewssuggestion is to consider offering to
women with vaginal bleeding and a his-
tory of 1 or more previous mis-
carriage(s) a course of treatment with
vaginal micronized progesterone 400 mg
twice daily, started at the time of pre-
sentation with vaginal bleeding and
continued to 16 completed weeks of
gestation. In the United Kingdom, we
estimate that implementing this treat-
ment strategy would result in an addi-
tional 8450 live births per year. We
believe that a woman at high risk of
having a miscarriage may not need ab-
solute scientific certainty to choose to
have a treatment. If she is informed
about the uncertainty around treatment
effects and available safety data, then she
could decide for herself the right course
of action. Policy makers and guideline
developers will need to consider the ev-
idence carefully to make a balanced
recommendation.
Implications for research
Further research is required to enhance
our understanding of LPD and develop
and validate tests to identify womenwith
LPD-related pregnancy losses. The
increased effectiveness of progesterone
with increasing number of miscarriages
indicates that endometrial defects are a
major driver of higher-order mis-
carriages. Yet, even after multiple mis-
carriages, the live birth rate and
cumulative live birth rate in these pa-
tients remain high. Presumably this
means that the underlying endometrial
defect is intermittent rather than
persistent; and that its frequency (ie,
number of “normal” vs “abnormal” cy-
cles) determines the likelihood of
miscarriage. This disease model is
compatible with emerging biology
demonstrating that the tissue homeo-
stasis in the cycling endometrium is
dependent on recruitment of bone
marrowederived stem cells and uterine
natural killer cells. Both “homeostatic”
mechanisms are perturbed in recurrent
miscarriage.24e26 A “dynamic” disease
model may help to explain the failure of
current diagnostic approaches, such as
screening for luteal-phase defects.
Currently, we rely on clinical history
to profile patients who may have a highrisk of progesterone-related problems.
However, this is imprecise. Accurate
endometrial tests may allow more pre-
cise targeting of patients who may
benefit from progesterone treatment.
Karyotyping all pregnancy losses may
also help to better risk-stratify women
who may benefit from progesterone
therapy; the role of routine karyotyping
using modern genetic analysis needs
further research, including the health
economic implications of such an
approach. Our research focused on
first-trimester use of progesterone;AUGUST 2020 Amresearch is also needed to explore the
effects of luteal phase progesterone use.
Development and validation of tests,
and therapeutic trials to determine the
efficacy of luteal phase progesterone
and other potential inteventions, are
needed. Finally, the PROMISE and
PRISM trials did not find any evidence
of an increase in congenital abnorma-
lites or short-term harm. The PROM-
ISE trial, involving 836 participants,
found no difference between the treat-
ment and the placebo group for the
outcomes of “any congenital anomaly”erican Journal of Obstetrics& Gynecology 175
Expert Reviews ajog.org(8/266 progesterone arm, 11/276
placebo arm, P¼.54) and “genital
congenital anomaly” (1/266 progester-
one arm, 1/276 placebo arm, P¼.98).12
The PRISM study, involving 4153
women, found no difference between
women treated with vaginal micronized
progesterone and those receiving pla-
cebo for the outcome of “congenital,
familial, and genetic disorders” (23/
2025 progesterone arm, 22/2013 pla-
cebo arm, P¼.90).10 However, we
recommend long-term follow up
studies of babies exposed to first-
trimester progesterone. -
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